Advanced Therapy Medicinal Products CDMO Market Size Worth $26.27 Billion By 2032 | CAGR: 18.8%

The global advanced therapy medicinal products CDMO market size is expected to reach USD 26.27 billion by 2032, according to a new study by Polaris Market Research. The report “Advanced Therapy Medicinal Products CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others); By Phase; By Indication; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The evolution of numerous diseases among the population and the ability to cure chronic health issues with the prevailing medicines is compelling researchers and government institutions to invest in genetic medicine and cell and tissue therapies. This ongoing trend is facilitating a compatible environment for pharmaceutical companies to innovate new therapies, driving the need for organizations that have the required infrastructure for the development, testing, and manufacturing of new therapies, necessitating the assistance of contract development and manufacturing organizations (CDMO).

The rising government initiatives to regulate the pharmaceutical industry are showing a positive impact on the advanced therapy medicinal products CDMO market growth opportunities. In September 2023, UK CDMO Rentschler Biopharma SE received approval to develop and supply adeno-associated virus vectors (AAV) for gene therapy, including bioprocessing and cGMP production, from the Medicines & Healthcare Products Regulatory Agency.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/advanced-therapy-medicinal-products-cdmo-market/request-for-sample

The growing strategic collaborations and partnerships to expand the research and development activities towards treating health problems are positively influencing the ATMP CDMO market. With the Histocell partnership, Reprocell will produce advanced therapies and medicinal products generated from mesenchymal stem cells.

Cell and gene therapy production is showing a positive outlook in the market. According to the Gene, Cell, & RNA Therapy Landscape Report, in Q3 2023, 27 gene therapies, 26 RNA therapies, and 65 non-genetically modified cell therapies, received approval for clinical use. The total number of gene therapies in phase 1 Q3 registered growth by 7% compared to Q1. This trend is demonstrating the potential demand to produce advanced therapeutic medicinal products, boosting the need for CDMO in the coming years.

The tissue engineering industry is gaining momentum in the marketplace, driven by its profound scope in the replacement, repair, and regeneration of tissues, which are used to cure skin, heart, liver, and lung tissue-related health problems. The rising research activities on the development of tissue engineering therapies are expected to drive the advanced therapy medicinal products CDMO market.

Advanced Therapy Medicinal Products CDMO Market Report Highlights

• Gene therapy segment is anticipated to witness the highest growth in the coming years due to the increasing clinical trials on gene therapies.
• Phase I segment accounted for the largest revenue share, owing to the rise in number of therapeutic developments.
• Oncology segment held the largest share, due to the rising number of cancer patients and its varied forms
• Asia pacific is projected to register the fastest growth during the forecast period, attributable to the growing investments in cell and gene therapies.
• The global players include AGC Biologics, Bio Elpida, BlueReg, Catalent, Celonic, CGT Catapult, Lonza, Medicine Patheon, & Minaris Regenerative.

Polaris Market Research has segmented the advanced therapy medicinal products CDMO market report based on product, phase, indication and region:

Advanced Therapy Medicinal Products CDMO, Product Outlook (Revenue - USD Billion, 2019 - 2032)

• Cell Therapy
• Gene Therapy

Advanced Therapy Medicinal Products CDMO, Phase Outlook (Revenue - USD Billion, 2019 - 2032)

• Phase I
• Phase II
• Phase III
• Phase IV

Advanced Therapy Medicinal Products CDMO, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

• Oncology
• Cardiology
• Central nervous system
• Musculoskeletal
• Infectious disease
• Dermatology
• Endocrine, metabolic, genetic
• Immunology & inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

Advanced Therapy Medicinal Products CDMO, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
• Latin America
  • Argentina
  • Brazil
  • Mexico
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Advanced Therapy Medicinal Products CDMO Market Report Scope